arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Cronos Group Inc.

CRON
$3.40 ▼ -0.02 (-0.58%) at close
Materials ·Medicinal Chemicals & Botanical Products ·USMedicinal Chemicals & Botanical Products
31 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
30
Health
Poor
Bearish
auto_awesome

Analytical Summary

Cronos Group Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.3B
Dividend Yield
Revenue Growth 58.4%
Op. Margin 14.0%
ROIC 0.7%
FCF / Share $0.06
Trailing P/E 37.8x
Price / Book 1.2x
FCF Yield 1.8%
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

31-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$53.01M
↑ +58.4%
Net Income Profit after all expenses
$32.09M
↑ +133.3%
Operating Margin Operating profit as % of sales
14.0%
↑ +444.5% 14th
FCF / Share Free cash flow per share
$0.06
↑ +150.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
20
Returns
43
Cash Quality
21

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 8 years · 31 quarters